34

nanotimes

Companies Facts

collect samples (like rodent serum, spinal fluid, tissue extracts, tears and dried blood spots) are possible. And with femtofluidic liquid handling, the NanoArray Assay System™ delivers rapid reaction kinetics and lowers reagent volumes, reducing assay costs.” http://www.nanoink.net/nanobio

N

anometrics Incorporated (NASDAQ: NANO), announced the opening of its Singapore Advan-

ced Metrology Center, an applications development center for customers using Nanometrics metrology systems. The center provides dedicated support throughout Asia for customers requiring advanced modeling of complex structures and recipe develop- ment. Nanometrics investment and commitment to additional applications resources reflects the rapid growth and adoption of optical critical dimension (OCD) technology in semiconductor manufacturing due to smaller, more complex structures and new materials.

Furthermore, Nanometrics announced a new release of NanoCD™ Suite, a turnkey optical critical dimen- sion (OCD) analysis solution with advanced modeling and recipe building capabilities. The suite, which is composed of high-performance software and hard- ware components, addresses process control requi- rements for semiconductor devices in production at 2x nm nodes and development at 1x nm nodes. The new product incorporates NanoDiffract™ 3.0, a pro- prietary OCD software engine broadly adopted by the world’s leading memory and logic customers and production proven at 2x nm technology nodes. http://www.nanometrics.com

N

anosphere, Inc. (NASDAQ: NSPH) released early stage research data on potential cancer

biomarkers requiring high sensitivity in an abstract for the annual meeting of the American Society of Clinical Oncology (ASCO, Chicago, USA, June 3 to 7, 2011). The early data suggests that three of Nanosphere‘s ultra-sensitive protein assays demons- trate potential clinical relevance in bladder, kidney and prostate cancers. The assays were developed and run using the Verisens™ high-throughput re- search platform. http://abstract.asco.org/AbstView_102_84952.html

F

or the 2010 fiscal year, Frankfurt-based nano- technology investment company Nanostart AG

(OTCQX: NASRY) reports the biggest profit in its company history. Net income under German GAAP totaled EUR2.48 million, up 106% on the previous year (2009: EUR1.2 million). This means another successful year for Nanostart, which has been profita- ble from the beginning of operations.

Net income stemmed chiefly from the successful sale of shares in holdings, which raised around EUR4.4 million. In contrast to the previous year, costs were reduced, particularly for wages and salaries (2010: EUR-0.5 million, 2009: EUR-1 million). As a result of sound performance levels in the portfolio, the “write- downs on financial investments” item was halved from EUR-1.4 million in 2009 to EUR-0.7 million in 2010.

The shares of Nanostart Singapore Early Stage Ven- ture Fund I in the Curiox Biosystems holding were sold in 2010. The transaction proceeds were plowed back into the fund and will be invested in new nano-

11-05 :: May/June 2011